Phase II Study of Neoadjuvant Treatment With Gemcitabine, Tarceva and Oxaliplatin Followed by Chemotherapy With Tarceva and Gemcitabine in Patients With Pancreas Adenocarcinoma With Borderline Resectability.

Trial Profile

Phase II Study of Neoadjuvant Treatment With Gemcitabine, Tarceva and Oxaliplatin Followed by Chemotherapy With Tarceva and Gemcitabine in Patients With Pancreas Adenocarcinoma With Borderline Resectability.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms GEMERLOXA
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top